Impact of tumor burden at progression and changes in risk scores from baseline in patients with advanced renal cell carcinoma treated with lenvatinib + pembrolizumab: Phase 3 CLEAR trial Meeting Abstract
| Authors: | Grünwald, V.; Keizman, D.; Bedke, J.; Staehler, M. D.; Matveev, V. B.; George, S.; Hutson, T. E.; Vaishampayan, U. N.; Merchan, J. R.; Eto, M.; Rha, S. Y.; Waddell, T.; Sabbatini, R.; Barthelemy, P.; Burgents, J. E.; Ren, M.; Brown, I.; Saal, H.; Choueiri, T. K.; Motzer, R. J. |
| Abstract Title: | Impact of tumor burden at progression and changes in risk scores from baseline in patients with advanced renal cell carcinoma treated with lenvatinib + pembrolizumab: Phase 3 CLEAR trial |
| Meeting Title: | 2025 ANZUP Annual Scientific Meeting |
| Journal Title: | Asia-Pacific Journal of Clinical Oncology |
| Volume: | 21 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2025 Jul 20-22 |
| Meeting Location: | Sydney, Australia |
| ISSN: | 1743-7555 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2025-07-01 |
| Start Page: | 81 |
| End Page: | 82 |
| Language: | English |
| ACCESSION: | WOS:001552871000037 |
| PROVIDER: | wos |
| DOI: | 10.1111/ajco.14216 |
| Notes: | Meeting Abstract: #abs37 -- Source: Wos |
